Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 116.49 Million CNY | -152.13% |
| 2022 | 19.47 Million CNY | 20.27% |
| 2021 | -1.19 Million CNY | -40.54% |
| 2020 | -148.57 Million CNY | -52.34% |
| 2019 | 34.51 Million CNY | -39.8% |
| 2018 | 281.57 Million CNY | 36.14% |
| 2017 | 179.69 Million CNY | 1.12% |
| 2016 | 144.74 Million CNY | 7.51% |
| 2015 | 183.24 Million CNY | 51.64% |
| 2014 | 127.61 Million CNY | -15.55% |
| 2013 | 160.6 Million CNY | 34.46% |
| 2012 | 118.56 Million CNY | -5.16% |
| 2011 | 125.25 Million CNY | 92.98% |
| 2010 | 64.9 Million CNY | 7.53% |
| 2009 | 60.24 Million CNY | 26.78% |
| 2008 | 47.18 Million CNY | 51.92% |
| 2007 | 33.91 Million CNY | 51.22% |
| 2006 | 18.86 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -10.91 Million CNY | 746.35% |
| 2024 Q3 | -24.5 Million CNY | -166.72% |
| 2024 Q1 | 7.08 Million CNY | -96.27% |
| 2023 Q3 | 7.24 Million CNY | 113.9% |
| 2023 Q4 | -19.61 Million CNY | -370.93% |
| 2023 Q2 | -52.08 Million CNY | -3804.7% |
| 2023 FY | - CNY | -152.13% |
| 2023 Q1 | 1.4 Million CNY | 109.62% |
| 2022 Q1 | -13.85 Million CNY | 83.21% |
| 2022 Q2 | -13.1 Million CNY | 5.42% |
| 2022 Q3 | 28.14 Million CNY | 314.75% |
| 2022 Q4 | -14.6 Million CNY | -151.9% |
| 2022 FY | - CNY | 20.27% |
| 2021 Q4 | -82.51 Million CNY | -737.29% |
| 2021 FY | - CNY | -40.54% |
| 2021 Q2 | -11.83 Million CNY | -114.46% |
| 2021 Q3 | -9.85 Million CNY | 16.7% |
| 2021 Q1 | 81.8 Million CNY | 189.26% |
| 2020 Q2 | 35.5 Million CNY | 758.67% |
| 2020 Q4 | -91.64 Million CNY | -392.87% |
| 2020 Q1 | 4.13 Million CNY | 106.2% |
| 2020 FY | - CNY | -52.34% |
| 2020 Q3 | 31.29 Million CNY | -11.86% |
| 2019 Q3 | 38.48 Million CNY | -39.51% |
| 2019 FY | - CNY | -39.8% |
| 2019 Q1 | 40.87 Million CNY | -5.8% |
| 2019 Q2 | 63.62 Million CNY | 55.66% |
| 2019 Q4 | -66.71 Million CNY | -273.35% |
| 2018 FY | - CNY | 36.14% |
| 2018 Q4 | 43.38 Million CNY | 26.04% |
| 2018 Q3 | 34.42 Million CNY | -58.89% |
| 2018 Q2 | 83.74 Million CNY | 120.66% |
| 2018 Q1 | 37.95 Million CNY | 178.88% |
| 2017 Q1 | 29.52 Million CNY | -13.98% |
| 2017 Q3 | 42.74 Million CNY | 13.3% |
| 2017 FY | - CNY | 1.12% |
| 2017 Q4 | 13.6 Million CNY | -68.16% |
| 2017 Q2 | 37.72 Million CNY | 27.76% |
| 2016 FY | - CNY | 7.51% |
| 2016 Q1 | 25.73 Million CNY | -34.41% |
| 2016 Q2 | 35.26 Million CNY | 37.03% |
| 2016 Q3 | 34.3 Million CNY | -2.71% |
| 2016 Q4 | 34.32 Million CNY | 0.05% |
| 2015 Q2 | 22.09 Million CNY | 6.77% |
| 2015 Q1 | 20.69 Million CNY | -32.24% |
| 2015 Q3 | 14.25 Million CNY | -35.5% |
| 2015 FY | - CNY | 51.64% |
| 2015 Q4 | 39.23 Million CNY | 175.32% |
| 2014 Q3 | 31.08 Million CNY | 292.93% |
| 2014 Q4 | 30.53 Million CNY | -1.75% |
| 2014 Q2 | 7.91 Million CNY | 218.04% |
| 2014 Q1 | -6.7 Million CNY | -115.25% |
| 2014 FY | - CNY | -15.55% |
| 2013 Q4 | 43.94 Million CNY | 119.83% |
| 2013 Q3 | 19.99 Million CNY | -53.1% |
| 2013 Q2 | 42.62 Million CNY | 103.16% |
| 2013 Q1 | 20.97 Million CNY | 120.95% |
| 2013 FY | - CNY | 34.46% |
| 2012 FY | - CNY | -5.16% |
| 2012 Q3 | 24.57 Million CNY | 6.0% |
| 2012 Q2 | 23.18 Million CNY | -26.73% |
| 2012 Q4 | 9.49 Million CNY | -61.36% |
| 2012 Q1 | 31.63 Million CNY | -14.48% |
| 2011 Q2 | 36.86 Million CNY | 33.29% |
| 2011 FY | - CNY | 92.98% |
| 2011 Q1 | 27.66 Million CNY | 56.04% |
| 2011 Q4 | 36.99 Million CNY | 82.68% |
| 2011 Q3 | 20.25 Million CNY | -45.07% |
| 2010 Q1 | 15.69 Million CNY | 12.16% |
| 2010 Q3 | 9.97 Million CNY | -24.52% |
| 2010 Q4 | 17.72 Million CNY | 77.68% |
| 2010 FY | - CNY | 7.53% |
| 2010 Q2 | 13.21 Million CNY | -15.8% |
| 2009 FY | - CNY | 26.78% |
| 2009 Q4 | 13.99 Million CNY | 1.72% |
| 2009 Q3 | 13.76 Million CNY | 34.97% |
| 2009 Q2 | 10.19 Million CNY | -31.93% |
| 2009 Q1 | 14.97 Million CNY | 21.7% |
| 2008 FY | - CNY | 51.92% |
| 2008 Q4 | 12.3 Million CNY | 9.22% |
| 2008 Q3 | 11.26 Million CNY | 0.0% |
| 2007 FY | - CNY | 51.22% |
| 2006 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 1.14 Billion CNY | 89.796% |
| Zhejiang Zhenyuan Share Co., Ltd. | 220.46 Million CNY | 47.159% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -83.34 Million CNY | 239.777% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -2.67 Million CNY | 4460.255% |
| Yifan Pharmaceutical Co., Ltd. | -483.52 Million CNY | 124.093% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 66.15 Million CNY | -76.104% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 4.85 Billion CNY | 97.602% |
| Boai NKY Medical Holdings Ltd. | 665.28 Million CNY | 82.49% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 391.09 Million CNY | 70.213% |